North China Pharmaceutical Company.Ltd Stock price

Equities

600812

CNE000000D16

Pharmaceuticals

End-of-day quote Shanghai S.E. 07:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
4.75 CNY +0.64% Intraday chart for North China Pharmaceutical Company.Ltd -4.23% -16.67%
Sales 2021 10.38B 1.44B Sales 2022 10.5B 1.45B Capitalization 10.98B 1.52B
Net income 2021 18M 2.49M Net income 2022 -689M -95.44M EV / Sales 2021 2.79 x
Net Debt 2021 8.47B 1.17B Net Debt 2022 9.37B 1.3B EV / Sales 2022 1.94 x
P/E ratio 2021
1,084 x
P/E ratio 2022
-15.9 x
Employees 10,952
Yield 2021
0.5%
Yield 2022
-
Free-Float 41.8%
More Fundamentals * Assessed data
Dynamic Chart
North China Pharmaceutical Subsidiary Gets Europe's Compliance Certification for Drug Raw Material MT
Jizhong Energy Group Finance Co., Ltd announced that it has received CNY 1.3 billion in funding from Jizhong Energy Group Co.,Ltd., Jizhong Energy Resources Co., Ltd., North China Pharmaceutical Company.Ltd CI
North China Pharmaceutical Gets Nod to Market Ampicillin API MT
North China Pharmaceutical Company.Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
North China Pharmaceutical Company.Ltd(XSSC:600812) added to S&P Global BMI Index CI
North China Pharmaceutical Company.Ltd(XSSC:600812) added to FTSE All-World Index CI
North China Pharmaceutical Company.Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Jizhong Energy Group Finance Co., Ltd announced that it expects to receive CNY 1.3 billion in funding from Jizhong Energy Group Co.,Ltd., Jizhong Energy Resources Co., Ltd., North China Pharmaceutical Company.Ltd CI
North China Pharmaceutical Company Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
North China Pharma Unit Passes Compliance Inspection MT
North China Pharmaceutical's Heart Drug Passes Regulatory Evaluation MT
North China Pharmaceutical Company Ltd.(SHSE:600812) dropped from Shanghai Stock Exchange Health Care Sector Index CI
North China Pharmaceutical Company Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
North China Pharmaceutical Company Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
North China Pharmaceutical Company Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
More news
1 day+0.64%
1 week-4.23%
Current month-4.81%
1 month-2.46%
3 months-16.81%
6 months-16.08%
Current year-16.67%
More quotes
1 week
4.62
Extreme 4.62
4.91
1 month
4.62
Extreme 4.62
5.03
Current year
3.83
Extreme 3.83
5.77
1 year
3.83
Extreme 3.83
6.66
3 years
3.83
Extreme 3.83
13.45
5 years
3.83
Extreme 3.83
20.24
10 years
3.83
Extreme 3.83
20.24
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 18-08-27
Director of Finance/CFO 53 09-08-31
Director/Board Member 54 20-01-31
Members of the board TitleAgeSince
Director/Board Member 47 16-03-21
Director/Board Member 58 19-05-21
Director/Board Member 69 19-05-21
More insiders
Date Price Change Volume
24-03-28 4.75 +0.64% 8 761 700
24-03-28 4.72 +1.94% 9,840,077
24-03-27 4.63 -1.28% 8,786,650
24-03-26 4.69 -1.47% 10,114,600
24-03-25 4.76 -1.86% 10,237,110

End-of-day quote Shanghai S.E., March 28, 2024

More quotes
North China Pharmaceutical Co., Ltd. is a China based company principally engaged in the research and development, production and sales of pharmaceuticals. The Company is mainly engaged in the research and development, production and sales of chemical raw materials, chemical preparations, biological preparations, pharmaceutical intermediates and nutraceuticals. The Company's products are covered in infective drugs, biotech drugs, cardio cerebrovascular drugs, nephropathy and immunomodulatory drugs, cancer therapeutic drugs, vitamins and nutraceuticals. In addition, The Company is also engaged in pharmaceutical logistics business. The Company distributes its products within the domestic market and to overseas markets.
Calendar
More about the company
  1. Stock
  2. Equities
  3. Stock North China Pharmaceutical Company.Ltd - Shanghai S.E.